Venetoclax added to conditioning before stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have MDS, CMML, or sAML with >5% marrow blasts and/or high-risk genetic features
- You have a matched donor for stem cell transplant (10/10 match, related or unrelated)
- You have not had more than 2 rounds of azacitidine or decitabine (you may have taken hydroxyurea by mouth)
- Your overall health is good enough for treatment (ECOG 0–2, and you can follow the visit schedule)
- There must be no active, uncontrolled infection and no known serious heart/liver/kidney/lung limits that make the trial unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This study tests a combination of venetoclax (a targeted drug) with a mini stem cell transplant (called a microtransplant) using a partially matched donor. It is for people with higher-risk MDS who cannot have a standard transplant.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.